Skip to main content

Table 4 Treatment-related adverse events (≥0.4%) according to patient age

From: Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results

Adverse event, n (%)

Age <70 years (n = 1297)

ge ≥70 years (n = 480)

Age <75 years (n = 1571)

Age ≥75 years (n = 206)

Diarrhoea

36 (2.8)

13 (2.7)

45 (2.9)

4 (1.9)

Nausea

29 (2.2)

4 (0.8)

30 (1.9)

3 (1.5)

Hypertension

15 (1.2)

8 (1.7)

23 (1.5)

0

Bleeding

17 (1.3)

4 (0.8)

18 (1.1)

3 (1.5)

Leucopenia

7 (0.5)

1 (0.2)

8 (0.5)

0

Infection

6 (0.5)

2 (0.4)

8 (0.5)

0

Proteinuria

5 (0.4)

2 (0.4)

5 (0.3)

2 (1.0)

Phlebitis/thrombosis/embolism

11 (0.8)

6 (1.3)

15 (1.0)

2 (1.0)